For first time in India, PredOmix launches blood test for early cancer detection

OncoVeryx-F is capable of detecting early-stage cancers in women with 98% accuracy

0
117
New Delhi: PredOmix, a health technology pioneer and innovation-driven company, has unveiled one of its kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with a 98% accuracy.
Backed by advanced metabolomics technology coupled with AI, the new-age innovation will enable the screening for early-stage cancers. Designed for women, the screening tool accurately diagnoses cancer before tumor development begins.
According to the Lancet study on the disease, India is first in terms of the number of cervical cancer cases after India. The research revealed that out of 40% of the total deaths from cervical cancer, 23% occurred in India. Ovarian cancer is characterized by a few early symptoms, presentation at an advanced stage, and poor survival. As a result, it is the most frequent cause of death from gynecological cancer. During the last decade, a research effort has been directed toward improving outcomes for ovarian cancer by screening for preclinical, early-stage disease using both imaging techniques and serum markers.

Backed by advanced metabolomics technology coupled with AI, the new-age innovation will enable the screening for early-stage cancers

OncoVeryx-F is a patented technology that combines metabolomics and artificial intelligence to detect early cancers. It is a blood-based screening approach that accurately identifies four major female-specific malignancies in a single blood test: breast, endometrium, cervix, and ovary. This is one of the first of its kind Multi Cancer Early Detection (MCED) blood test developed by PredOmix that is now available in India and will aid in determining the presence or absence of cancer as well as the tissue of origin or cancer type.
Dr. Kanury V S Rao, Co-Founder & Chief Scientific Officer (CSO), PredOmix, said, “ Our cancer screening test’s accuracy rates are over 98 percent. OncoVeryx-F has an extremely high specificity for detecting early stages of cancer from a very small quantity of blood samples. We have been successful in demonstrating outcomes for four women cancers including breast cancer and even ovarian cancers which is known to be a silent killer”. Our company has plans to expand its testing capabilities by 2023 for detecting 17 types of cancers in both men and women.
“As an introductory offer, we are offering the women-specific multi-cancer test at a 50% discount. The test is nominally priced at Rs. 12,000”, he adds.
Dr. Pravin Poddar, Scientific Advisor PredOmix, says, “It’s a non-intrusive technique without any preliminary requirements of biopsy. This innovation will help find the location of the cancer cells’ growth alongside detecting cancer onset without using invasive techniques. Early diagnosis can definitely aid timely treatment-related decisions and potentially save lives”.